29. September 2015

New: Recombinant Gliadin Peptides



Pure gliadin peptides, recombinantly produced as easy-to-handle fusion with a carrier protein are now available.
In addition we provide antibodies to gliadin and cereal protein extracts like wheat gliadin for your research.

Find below the selection of our Recombinant Gliadin Peptides:

Art. No.    Name           Unit     Price
G051   26mer γ-gliadin peptide   26mer gamma-gliadin peptide   250 µg   370 €
G052   33mer α-gliadin peptide   33mer alpha-gliadin peptide   250 µg   370 €
G055   Carrier protein control   carrier protein control   250 µg   370 €
G053   26mer DGP (DGPx1)   26mer DGPx1   250 µg   370 €
G054   33mer DGP   33mer DGP   250 µg   370 €
G006   DGPx2   DGPx2   500 µg   735 €
G005   DGPx4   DGPx4   500 µg   735 €
                 
G056

  DGP and Gliadin peptides (Set No 1)
(G051, G052, G053, G054 and G055, 100 µg each)
      1 Set   740 €
                 

Corresponding research tools:

Antibodies to gliadin
                 
Art. No.   Name       Unit   Price
A011


  Monoclonal antibody to gliadin (clone XGY1)
(recognizes 26mer γ-gliadin peptide [G051], but not 33mer α-gliadin)
  1 mg   365 €
A064



  Monoclonal antibody to gliadin (clone XGY4)
(recognizes 26mer γ-gliadin peptide [G051], and 33mer α-gliadin [G052] and
corresponding DGP’s [G053, G054, G006, G005])
  1 mg   365 €
A057

  Monoclonal antibody to deamidated Gliadin
(specific to 33mer DGP [G054])
  100 µg   480 €
                 
Find further antibodies against gliadin and deamidated gliadin on our website www.zedira.com/Antibodies/Wheat-Gliadin.

Cereal Proteins
                 
Art. No.   Name       Unit   Price
G037   Wheat prolamin (Gliadin)   5 mg   195 €
                 
Albumin + globulin, prolamin and glutelin extracts from the cereals listed below are available: www.zedira.com/Cereal-Proteins.

Cereal Proteins

Document

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • Life Sciences 2019: Post-translational modifications and cell signalling

    17.03.2019 - 18.03.2019
    Nottingham, UK

  • 10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)

    16.05.2019 - 17.05.2019
    Sheffield, UK

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France